RT Journal Article
SR Electronic
T1 SARS-CoV-2 containment was achievable during the early stage of the pandemic: a retrospective modelling study of the Xinfadi outbreak in Beijing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.12.22279850
DO 10.1101/2022.09.12.22279850
A1 Wang, Yan
A1 Sun, Kaiyuan
A1 Pan, Yang
A1 Yi, Lan
A1 Huo, Da
A1 Wu, Yanpeng
A1 Dong, Shuaibing
A1 Guo, Jinxin
A1 Dou, Xiangfeng
A1 Wang, Wei
A1 Wu, Shuangsheng
A1 Bai, Xufang
A1 Yu, Hongjie
A1 Wang, Quanyi
YR 2022
UL http://medrxiv.org/content/early/2022/09/14/2022.09.12.22279850.abstract
AB Prior to the emergence of the Omicron variant, many cities in China had been able to maintain a “Zero-COVID” policy. They were able to achieve this without blanket city-wide lockdown and through widespread testing and an extensive set of nonpharmaceutical interventions (NPIs), such as mask wearing, contact tracing, and social distancing. We wanted to examine the effectiveness of such a policy in containing SARS-CoV-2 in the early stage of the pandemic. Therefore, we developed a fully stochastic, spatially structured, agent-based model of SARS-CoV-2 ancestral strain and reconstructed the Beijing Xinfadi outbreak through computational simulations. We found that screening for symptoms and among high-risk populations served as methods to discover cryptic community transmission in the early stage of the outbreak. Effective contact tracing could greatly reduce transmission. Targeted community lockdown and temporal mobility restriction could slow down the spatial spread of the virus, with much less of the population being affected. Population-wide mass testing could further improve the speed at which the outbreak is contained. Our analysis suggests that the containment of SARS-CoV-2 ancestral strains was certainly possible. Outbreak suppression and containment at the beginning of the pandemic, before the virus had the opportunity to undergo extensive adaptive evolution with increasing fitness in the human population, could be much more cost-effective in averting the overall pandemic disease burden and socioeconomic cost.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by grants from the Key Program of the National Natural Science Foundation of China (82130093)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval and informed consent requirements were waived by the Institutional Review Board and Human Research Ethics Committee of the Beijing Center for Disease Prevention and Control (Beijing CDC) because this study was considered a continuation of the public health investigation associated with an emerging infectious disease.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors